COVID-19: PeaceHealth is open, with safe virtual and in-person visits.
Learn more about our safety measures and visitor restrictions.

Melanoma 

  • A091802: Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
  • S1801: Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
  • EA6134: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  • S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent

For more information, contact Lauren Key, 360-788-8238